Beckman Coulter has entered into a strategic alliance with CaridianBCT, under the terms of which Beckman Coulter will market CaridianBCT cell therapy products in specific, targeted markets.
CaridianBCT and Beckman Coulter are to launch CaridianBCT's Quantum cell expansion system, a closed system that automates the cell expansion process, along with marketing CaridianBCT's Cobe 2991 cell processor, a system that washes and concentrates cell populations, and the Elutra cell separation system, which purifies cell populations via elutriation.
Adding the Quantum, Elutra and Cobe 2991 systems to the Beckman Coulter line of products for cell sorting, cellular analysis and characterisation will enable the company to provide pharmaceutical companies, research institutes and clinical trial organisations with a full line of cellular discovery systems.
CaridianBCT will retain the distribution rights to these cell therapy products in other market segments, including commercial cell therapy developers, cell therapy contract manufacturing organisations, the veterinary market, and the cord-blood bank and blood bank markets.
